AU2003237664A1 - Formulation for parenteral administration of sodium channel blockers - Google Patents

Formulation for parenteral administration of sodium channel blockers

Info

Publication number
AU2003237664A1
AU2003237664A1 AU2003237664A AU2003237664A AU2003237664A1 AU 2003237664 A1 AU2003237664 A1 AU 2003237664A1 AU 2003237664 A AU2003237664 A AU 2003237664A AU 2003237664 A AU2003237664 A AU 2003237664A AU 2003237664 A1 AU2003237664 A1 AU 2003237664A1
Authority
AU
Australia
Prior art keywords
formulation
parenteral administration
sodium channel
channel blockers
blockers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003237664A
Inventor
Bernd Kruss
Annerose Mauz
Karin Ruhr
Jean-Marie Stassen
Claus Veit
Klaus Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Publication of AU2003237664A1 publication Critical patent/AU2003237664A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003237664A 2002-05-29 2003-05-23 Formulation for parenteral administration of sodium channel blockers Abandoned AU2003237664A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10223783.2 2002-05-29
DE10223783A DE10223783A1 (en) 2002-05-29 2002-05-29 New formulation for parenteral administration of a Na-channel blocker
PCT/EP2003/005399 WO2003099336A1 (en) 2002-05-29 2003-05-23 Formulation for parenteral administration of sodium channel blockers

Publications (1)

Publication Number Publication Date
AU2003237664A1 true AU2003237664A1 (en) 2003-12-12

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003237664A Abandoned AU2003237664A1 (en) 2002-05-29 2003-05-23 Formulation for parenteral administration of sodium channel blockers

Country Status (12)

Country Link
EP (1) EP1511517B1 (en)
JP (1) JP2005527615A (en)
AR (1) AR040134A1 (en)
AT (1) ATE373492T1 (en)
AU (1) AU2003237664A1 (en)
CA (1) CA2487150A1 (en)
DE (2) DE10223783A1 (en)
ES (1) ES2294295T3 (en)
PE (1) PE20040066A1 (en)
TW (1) TW200400029A (en)
UY (1) UY27823A1 (en)
WO (1) WO2003099336A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (en) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilized superoxide dismutase (SOD) composition
DE4313408A1 (en) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-biocid complex
FR2713934B1 (en) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Use of amino cyclodextrins for the aqueous solubilization of hydrophobic compounds, in particular of pharmaceutically active molecules.
DE19740110A1 (en) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma New hydroxy substituted benzomorphan derivatives
WO2002007772A2 (en) * 2000-07-24 2002-01-31 Boehringer Ingelheim Pharmaceuticals, Inc. Improved oral dosage formulations
DE10223784A1 (en) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma New formulation for parenteral administration of crobenetine

Also Published As

Publication number Publication date
DE10223783A1 (en) 2003-12-11
CA2487150A1 (en) 2003-12-04
ATE373492T1 (en) 2007-10-15
JP2005527615A (en) 2005-09-15
TW200400029A (en) 2004-01-01
WO2003099336A1 (en) 2003-12-04
AR040134A1 (en) 2005-03-16
PE20040066A1 (en) 2004-03-22
EP1511517B1 (en) 2007-09-19
DE50308227D1 (en) 2007-10-31
ES2294295T3 (en) 2008-04-01
EP1511517A1 (en) 2005-03-09
UY27823A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
AU2003302540A1 (en) Synchronization of signals
AU2003272590A1 (en) Method for ophtalmic administration of medicament
AU2003296897A1 (en) Pharmaceutical formulations of camptothecine derivatives
AU2003250690A1 (en) Auto-characterization of optical devices
AU2003268087A1 (en) Liposomal gemcitabine compositions for better drug delivery
AU2003276323A1 (en) Arranging synchronization session
AU2003224969A1 (en) Radio interface synchronization
AU2003299838A1 (en) Ingestible formulations for transient, noninvasive reduction of gastric volume
AU2002353180A1 (en) Use of ugt inhibitors to increase bioavailability
AU2003226189A1 (en) Oral administration of epothilones
AU2003251247A1 (en) Methods for preparation of olanzapine polymorphic form i
EP1501509A4 (en) Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
AU2003221577A1 (en) Entitlements administration
AU2003224981A1 (en) Preparation of nanosized copper (i) compounds
AU2003250317A1 (en) Device for administration of fluids
AU2003297693A1 (en) Splice variant of human sodium iii channel (hnaiii18)
IL161560A0 (en) Anthelmintic compositions containing milbemycin derivatives
AU2002338201A1 (en) Anthelmintic composition
AU2003900505A0 (en) Anthelmintic composition
AU2003297597A1 (en) Benzimidazoles and analogs thereof as antibacterials
AU2003237664A1 (en) Formulation for parenteral administration of sodium channel blockers
AU2003300543A1 (en) Slow release formulation of clarithromycin
EP1501790A4 (en) Novel sodium channel blockers
AU2002343199A1 (en) Formulations of erythromycin derivatives with improved bioavailability
AU2003241150A1 (en) Novel polymorphs of pantoprazole sodium

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase